[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) increases 4.7% this week, taking one-year gains to 24%",
    "summary": "There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But not every stock you...",
    "url": "https://finnhub.io/api/news?id=74a6054a5d4243ad4092fbf057b5a469ff971302c4cd7089df008f29b3ca2bc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732449627,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) increases 4.7% this week, taking one-year gains to 24%",
      "id": 131614360,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/61ae5b4abdbb9c040fe4f1989e525046",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But not every stock you...",
      "url": "https://finnhub.io/api/news?id=74a6054a5d4243ad4092fbf057b5a469ff971302c4cd7089df008f29b3ca2bc8"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Bristol Myers Squibb Be in 5 Years?",
    "summary": "Investors often look to major pharmaceutical stocks as an area that is likely to provide an anchor for their portfolios.  Consider Bristol Myers Squibb (NYSE: BMY), which has seen its shares rise just 2% over the past five years, seesawing back and forth over that time.  Its trailing-12-month operating expenses of $28.2 billion are substantially higher than its operating income of around $7.3 billion over that period.",
    "url": "https://finnhub.io/api/news?id=d98bb9569c332c7072a3122ee4f081110fe0b8eff350591086ca0c88870b02db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732447800,
      "headline": "Where Will Bristol Myers Squibb Be in 5 Years?",
      "id": 131617890,
      "image": "https://g.foolcdn.com/editorial/images/798496/three-scientists-chat-at-a-lab-bay.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investors often look to major pharmaceutical stocks as an area that is likely to provide an anchor for their portfolios.  Consider Bristol Myers Squibb (NYSE: BMY), which has seen its shares rise just 2% over the past five years, seesawing back and forth over that time.  Its trailing-12-month operating expenses of $28.2 billion are substantially higher than its operating income of around $7.3 billion over that period.",
      "url": "https://finnhub.io/api/news?id=d98bb9569c332c7072a3122ee4f081110fe0b8eff350591086ca0c88870b02db"
    }
  }
]